Eagle Pharmaceuticals, Inc. (EGRX)

4.3100 +0.4800 (+12.53%) At close: 04:00PM EDT

Eagle Pharmaceuticals, Inc.

50 Tice Boulevard
Suite 315
Woodcliff Lake, NJ 07677
United States
201 326 5300
https://www.eagleus.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 134

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael Graves	Interim Principal Executive Officer & Executive Chairman of the Board	160k	N/A	1963
Mr. Steven B. Ratoff	Interim CFO, Principal Accounting Officer & Director	100k	N/A	1943
Mr. Daniel O'Connor	Executive VP, Chief Strategy Officer & Head of Corporate Development	N/A	N/A	1980
Dr. Valentin R. Curt M.D.	Senior Vice President of Clinical Drug Development	N/A	N/A	N/A
Dr. Gaozhong Zhu Ph.D.	Senior Vice President of Pharmaceutical Development	N/A	N/A	N/A
Ms. Debra Marie Hussain	Senior VP & Head of Commercial	N/A	N/A	1968
Mr. Reed McClung	Executive Vice President of Oncology Business Development	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Corporate governance

Eagle Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 September 2024 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder rights: 7; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.